公开(公告)号：EP1452150A1

公开(公告)日：2004-09-01

申请号：EP04076470.6

申请日：1998-05-08

申请人： ORGANOGENESIS INC.

发明人： Abraham, Ginger A ,  Carr, Robert M. Jnr. ,  Kemp, Paul D. ,  Mercer, Ryan ,  Baker, Linda

IPC分类号： A61F2/00 ,  A61F2/02 ,  A61F2/24 ,  A61F13/00 ,  A01N1/02 ,  A61L27/24 ,  A61L27/36

CPC分类号： A61L27/3687 ,  A61K35/12 ,  A61K38/39 ,  A61L27/24 ,  A61L27/3695 ,  A61L2430/40 ,  Y10S623/917 ,  Y10S623/92

摘要： The invention is directed to collagenous tissues which have been treated to remove non-collagenous components such as cells, cellular debris, and other extracellular matrix components, such as proteoglycans and glycosaminoglycans, normally found in native tissues. Treatment of the tissue with alkali, chelating agents, acids and salts removes non-collagenous components from the collagenous tissue matrix while controlling the amount of swelling and dissolution so that the resultant collagen matrix retains its structural organization, integrity and bioremodelable properties. The process circumvents the need to use detergents and enzymes which detrimentally affect the cell compatibility, strength and bioremodelability of the collagen matrix. The collagenous tissue matrix is used for implantation, repair, or use in a mammalian host.

摘要翻译： 本发明涉及已被处理以除去非胶原成分如胶原组织的细胞，细胞碎片和其它细胞外基质成分，例如通常存在于天然组织中的蛋白聚糖和糖胺聚糖。 用碱，螯合剂，酸和盐处理组织可以从胶原组织基质中去除非胶原成分，同时控制溶胀和溶解的量，使得所得胶原蛋白基质保持其结构组织，完整性和生物可重构性质。 该方法避免了使用有害地影响胶原基质的细胞相容性，强度和生物可塑性的洗涤剂和酶的需要。 胶原组织基质用于哺乳动物宿主植入，修复或使用。

公开(公告)号：EP1452150B1

公开(公告)日：2013-01-09

申请号：EP04076470.6

申请日：1998-05-08

申请人： ORGANOGENESIS INC.

发明人： Abraham, Ginger A ,  Carr, Robert M. Jr. ,  Kemp, Paul D. ,  Mercer, Ryan ,  Baker, Linda

IPC分类号： A61F2/00 ,  A61F2/02 ,  A61F2/24 ,  A61F13/00 ,  A01N1/02 ,  A61L27/24 ,  A61L27/36

CPC分类号： A61L27/3687 ,  A61K35/12 ,  A61K38/39 ,  A61L27/24 ,  A61L27/3695 ,  A61L2430/40 ,  Y10S623/917 ,  Y10S623/92

摘要： The invention is directed to collagenous tissues which have been treated to remove non-collagenous components such as cells, cellular debris, and other extracellular matrix components, such as proteoglycans and glycosaminoglycans, normally found in native tissues. Treatment of the tissue with alkali, chelating agents, acids and salts removes non-collagenous components from the collagenous tissue matrix while controlling the amount of swelling and dissolution so that the resultant collagen matrix retains its structural organization, integrity and bioremodelable properties. The process circumvents the need to use detergents and enzymes which detrimentally affect the cell compatibility, strength and bioremodelability of the collagen matrix. The collagenous tissue matrix is used for implantation, repair, or use in a mammalian host.